Research Article
Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study
Table 7
Yearly change (%) in uptake between baseline and 1-year followup: DAT and IBZM ratios.
| | N | Mean | 95% CI | Mann-Whitney U test | HC versus PD | HC versus MSA | HC versus PSP | PD versus MSA | PD versus PSP | MSA versus PSP | P | P | P | P | P | P |
| Contralateral∞ | | | | | | | | | | Caudate DAT | | | | | | | | | | PD | 27 | −8.0 | −11.6–−4.5 | 0.005 | ns | 0.006 | 0.013 | ns | 0.017 | MSA | 4 | 5.3 | −4.8–15.4 | PSP | 8 | −11.8 | −21.0–−2.7 | HC* | 14 | −0.5 | −2.2–1.3 | Putamen DAT | | | | | | | | | | PD | 27 | −6.5 | −10.8–−2.2 | ns | ns | 0.006 | ns | ns | ns | MSA | 4 | −3.3 | −14.4–7.8 | PSP | 8 | −13.9 | −23.0–−4.7 | HC* | 13 | −1.0 | −2.9–0.8 | Striate DAT | | | | | | | | | | PD | 27 | −7.2 | −10.6–−3.9 | 0.006 | ns | 0.004 | ns | ns | 0.042 | MSA | 4 | 0.8 | −10.4–11.9 | PSP | 8 | −12.8 | −21.6–−4.0 | HC* | 14 | −0.7 | −2.4–0.9 | Ipsilateral∞ | | | | | | | | | | Caudate DAT | | | | | | | | | | PD | 27 | −7.7 | −12.1–−3.4 | 0.045 | ns | 0.006 | 0.045 | ns | ns | MSA | 4 | 4.3 | −12.3–21.0 | PSP | 8 | −11.9 | −24.8–1.1 | HC* | 14 | −0.5 | −2.2–1.3 | Putamen DAT | | | | | | | | | | PD | 27 | −8.5 | −12.0–−4.9 | 0.006 | ns | 0.005 | ns | (0.054) | ns | MSA | 4 | −8.2 | −28.0–11.5 | PSP | 8 | −13.4 | −26.9–0.1 | HC* | 13 | −1.0 | −2.9–0.8 | Striate DAT | | | | | | | | | | PD | 27 | −8.3 | −11.7–−5.0 | 0.002 | ns | 0.004 | ns | ns | ns | MSA | 4 | −1.9 | −19.2–15.4 | PSP | 8 | −12.8 | −25.5–0.0 | HC* | 14 | −0.7 | −2.4–0.9 |
| Mean | | | | | | | | | | Striate IBZM | | | | | | | | | | PD | 29 | −3.1 | −6.2–0.0 | ns | ns | ns | ns | ns | ns | MSA | 5 | −4.7 | −8.7–−0.7 | PSP | 8 | −8.3 | −19.8–3.3 | HC* | 14 | −2.1 | −3.5–−0.8 |
|
|
HC: average yearly change calculated between baseline and the 3-year follow-up SPECT. ∞Patients with same laterality as baseline.
|